Pharma Leader Series - Leading Pharmaceutical Contract Manufacturing Organisations (CMOs) 2014-2024
LONDON, October 1, 2014 /PRNewswire/ --
Report Details
Contract manufacturing for pharma - discover top companies' revenue prospects
How are pharma contract manufacturing organisations (CMOs) performing? Visiongain's new report shows you their prospects to 2024. There you discover that industry and market's results, trends, opportunities and prospects, also with predicted revenues and profits.
Our study analyses 30 top CMOs. There you see how revenues from drug production services can increase. So what trends, technologies and opportunities most shape the future? You find out, benefiting your knowledge, decisions and authority.
That way you discover analysis on established and emerging companies across the world. Read on, then, to scan those organisations and see what their future market could be worth.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Forecasts and other data to help you stay ahead for commercial data
In that updated study you find analytical profiles of 30 top companies, and analyses of their overall industry. You discover historical data, market and sales shares, growth rates and revenue forecasts. See, too, qualitative analyses, business outlooks and developments.
There you gain 184 tables, 111 charts and five interviews with that industry.
Our work lets you assess the most lucrative services in outsourced drug making. That way you can stay ahead in understanding the CMO industry and market. And also benefit your research, analyses and influence. In particular, see prospects for these market segments:
- Active pharmaceutical ingredients (API) production
- Finished dosage formulations (FDF) manufacturing
There hear how you can benefit your work, also saving time and helping you stay ahead of competitors. And the following sections highlight what our updated investigation gives you.
Company profiles - activities, results, competition and prospects
- Our report analyses 30 leading companies. The content of each profile differs, depending on the organisation. In general, though, a profile gives you the following information:
- Overview of the company's contract manufacturing services, including clients
- Analysis of recent financial performance - annual revenue for CMO services, operating profit and margin
- Assessment of developments - activities, acquisitions, production capacity, deals, new service offerings and collaborations
SWOT analysis - a firm's strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2014 onwards - Forecasting of pharmaceutical manufacturing revenue to 2024 (for 28 firms), as well as projected operating profit and margin for some companies
- Transcript of an interview by visiongain (for five companies)
Discover there what participants offer, achieve, aim for and say, helping you stay ahead.
European contract manufacturing organisations
First our study gives you discussions, financial analyses and commercial outlooks for 14 European CMOs, including these firms:
- Lonza
- Evonik Degussa
- Royal DSM
- Boehringer Ingelheim
- Fareva
- Famar
- Vetter Pharma
Discover what the future holds for those pharma service providers, including revenue outlooks to 2024. What profitability and other achievements are possible?
CMOs based in the US and Japan
Next our report shows you developments and business outlooks for seven other medical production contractors:
- Catalent Pharma Solutions
- Patheon
- Baxter BioPharma Solutions
- AbbVie Contract Manufacturing
- Pfizer CentreSource
- Daito Pharmaceutical
- Nipro Corporation.
Our work shows you where sales growth can occur. Many opportunities remain, with high, expanding revenues forecasted from 2014. You discover where prospects exist, seeing what's possible.
Developed-market API specialists
You also discover outlooks for three top producers of active pharmaceutical ingredients:
- Teva API
- Esteve Química
- Euticals
Our report shows you potentials of that industry. You see possibilities for advancing medical technology and raising business performance, with better serving of clients.
India and China- analysis of pharma manufacturing service providers
Our work also assesses six Indian and Chinese companies. There you discover activities and prospects of these firms:
- Dr. Reddy's Laboratories
- Aurobindo Pharma
- Divis Laboratories
- Shandong Xinhua Pharmaceutical
- Zhejiang Hisun Pharmaceutical
- Zhejiang Huahai Pharmaceuticals
That way you find sales data and underlying trends, seeing what the present and future hold.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Predictions for the worldwide pharma CMO market and submarkets
Our report also forecasts revenues to 2024 for the world contract manufacturing industry and its main segments: APIs and FDFs.
There you see overall world revenues reaching $71bn in 2018. Our analyses reveal high sales expansion from 2014 to 2024. That work also predicts large companies and specialty healthcare firms will develop and prosper. She why, how and where, finding potentials.
In particular, biologics and biosimilars hold promise. New therapies - including antibody-drug conjugates, high potency APIs and regenerative medicines - interest CMOs and clients.
So discover opportunities and revenue predictions for outsourced production of medicines. You investigate established and rising companies, finding their potentials.
Ways Leading Pharmaceutical Contract Manufacturing Organisations (CMOs) 2014-2024 helps
In particular, our new investigation benefits your work through the following analyses:
- Revenues to 2024 for the world pharma contract manufacturing organisations (CMO) market - discover that industry's prospects, finding promising segments for investments and revenues
- Profiles of 30 leading companies there - assess services, strategies, sales results and outlooks, also gaining revenue forecasts to 2024 for 28 of the firms, and with profit predictions for some
- Interviews with five top companies in the CMO industry - find debates and opinions, helping you stay ahead
- Competition and opportunities - see what affects that industry, exploring what shapes its future, esp. prospects for sustaining and developing business
- Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and succeed
Information there found nowhere else, helping you research, analyse and plan
That work gives independent analysis. There you get business intelligence found only in our report, seeing where prospects are most rewarding.
By choosing our study you're less likely to fall behind in knowledge or miss opportunity. Discover there how you could benefit your research, analyses and decisions. Also see how you could save time and gain in recognition for technological and commercial insight.
Prospects for pharma manufacturing providers - try our new analysis now
Our new study gives you data, trends, opportunities and business predictions for outsourced drug and API production. Avoid missing out - instead please get our report here now.
To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel : +44 (0) 20 7336 6100
Companies Listed in this report
Abbott Laboratories
Abic
AbbVie
Actavis
Adamas Pharmaceuticals
Aegerion
Aenova Group
Aesica Pharmaceuticals
Agence Nationale de sécurité du Médicament et des produits de santé (ANSM)
Agência Nacional de Vigilância Sanitária (ANVISA)
Agennix
Aguettant
AlgoNomics
Alliance Medical Products
Almac Group
Alpharma
Amgen
AMYRA Biotech
Andeno
Apexigen
Aptuit
Archimica
Arecor
ArGEN-X
Astellas
AstraZeneca
Athera Biotechnologies
Aurobindo Pharma
Avalanche Biotechnologies
Banner Life Sciences
BaroFold
Barr-Pliva
BASF
Baxter BioPharma Solutions
Bayer
BC partners
Becton and Dickinson (BD)
Beijing Double-Crane Pharmaceutical
Bentley
Biocraft
Biogal
Biomedical Advanced Research and Development Authority (BARDA)
Bionomics
Biotest
BioWa
Boehringer Ingelheim
Bridgepoint Capital
Bristol-Myers Squibb
Britest
Canyon
Carbogen Amcis
Cardinal Health
Catalent
Celladon
Celldex Therapeutics
Celsion
CEVEC Pharmaceuticals
Chemtrix BV
China National Pharmaceutical Group (Sinopharm)
Chirotech
Circadian Technologies
Cleveland BioLabs
Cobra Biomanufacturing
Companies House
CordenPharma
Corvette Pharmaceutical Services
Daiichi Sankyo
Daito
DecImmune Therapeutics
Delmas Perfusion
Delpharm
Divis Laboratories
DPx Holdings
Dr. Reddy's Laboratories
Dragenopharm Apotheker Püschl and Swiss Caps
Eclipse Therapeutics
Eindhoven University of Technology
Eisai
Eli Lilly
EmulTech
Esteve Química
Euro Vital Pharma
European Medicines Agency (EMA)
Euticals
Evonik Degussa
Excella
Exelixis
Famar
Fareva
Farmaprojects
Frazier Healthcare
Fuyang Xinghai Investment
Genentech
Générique Même Médicament (GEMME)
Genzyme
GSK
Corixa
Haupt Pharma
Health Canada
Hejiang Jiang Yuan Tang Biotechnology
Human Genome Sciences
ICI
Immune Pharmaceuticals
Immunomedics
Index Ventures
Indoco Remedies
Intellect Neurosciences
International Chemical Investors Group
Ivax API
Japanese Ministry of Health Labor and Welfare (MHWL)
Japanese Pharmaceutical and Medical Devices Agency (PMDA)
JK Pharmaceutical
JLL Partners
Johnson & Johnson (J&J)
Kadmon
Laboratoires Besins
Lanxess Corporation
LBO Italia Investimenti s.r.l
Lonza
Marinopoulos Group.
MedImmune
Merck KGaA
Merck Serono
Mesoblast
Molecular Partners
Moody's Corporation
Mylan
NIH CRM
Nipro Corporation
Novartis
Novasep
Novozymes
NPS
OctoPlus
OncoMed Pharmaceuticals
Opthea
Osiris Therapeutics
Otsuka Pharmaceutical
Pantec
Patheon
Perrigo
PFC
Pfizer
Pharmacia
Pharmacyclis
Pharmintraco
Piramal
Plantex
Poli Industria Chimica
Progenics Pharmaceuticals
Prosintex
R5 Pharmaceuticals
RAG AG
Ranbaxy
Recipharm
Regeneus
Relthy Laboratórios
Relypsa
Respirics
Rexim
Roche
Royal DSM
Sandoz
Sanofi
Sanquin Blood Supply foundation
Sanwa Kagaku Kenkyusho
Schering
ScinoPharm
Seattle Genetics
Sentry BioPharma Services
Servier
Shandong Tianda Biological Pharmaceutica
Shandong Xinhua Pharmaceutical
Shanghai Pharmaceutical
ShangPharma
Shire
Sicor
Siegfried
Sigmar Italia
Silverfleet Capital
Sinochem
SkyePharma
Solvay
Sun Pharma
Supernus Pharmaceuticals
SurModics
Swedbank
Swedish Orphan Biovitrium AB (Sobi)
Synkem
Syntex
Synthon
Takeda
Temmler Group
Tessenderlo Group
Teva Pharmaceutical Industries
Theramax
Tianjin Tianyo Pharmaceuticals
Tianma Tianji
Tunitas Therapeutics
UCB
UK Health and Safety Executive
UK Medicines and Healthcare Products Regulatory Agency (MHRA)
UMN Pharma
UniQure
University College London (UCL)
University of Bradford
University of Durham
University of Leeds
US Food and Drug Administration (FDA)
Vetter Pharma
Vidara
ViroPharma
Vivante GMP Solutions
VTU Technology
West Pharma
Wockhardt
XOMA
Yiwu Huayi Investment
Zhangjiang Biotech & Pharmaceutical Base Company
Zhejiang Hisun Pharmaceutical
Zhejiang Huahai Pharmaceuticals
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Share this article